DOCSLIB.ORG

[email protected]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Characterization of the relationship between two RBM5 family members by Julie Jennifer Loiselle A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (PhD) in Biomolecular Sciences The Faculty of Graduate Studies Laurentian University Sudbury, Ontario, Canada © Julie Loiselle, 2017 THESIS DEFENCE COMMITTEE/COMITÉ DE SOUTENANCE DE THÈSE Laurentian Université/Université Laurentienne Faculty of Graduate Studies/Faculté des études supérieures Title of Thesis Titre de la thèse Characterization of the relationship between two RBM5 family members Name of Candidate Nom du candidat Loiselle, Julie Degree Diplôme Doctor of Philosophy Department/Program Date of Defence Département/Programme Biomolecular Sciences Date de la soutenance July 31,2017 APPROVED/APPROUVÉ Thesis Examiners/Examinateurs de thèse: Dr. Leslie Sutherland (Supervisor/Directeur(trice) de thèse) Dr. Eric Gauthier (Committee member/Membre du comité) Dr. Amadeo Parissenti (Committee member/Membre du comité) Approved for the Faculty of Graduate Studies Approuvé pour la Faculté des études supérieures Dr. David Lesbarrères Monsieur David Lesbarrères Dr. Doug Gray Dean, Faculty of Graduate Studies (External Examiner/Examinateur externe) Doyen, Faculté des études supérieures Dr. T.C. Tai (Internal Examiner/Examinateur interne) ACCESSIBILITY CLAUSE AND PERMISSION TO USE I, Julie Loiselle, hereby grant to Laurentian University and/or its agents the non-exclusive license to archive and make accessible my thesis, dissertation, or project report in whole or in part in all forms of media, now or for the duration of my copyright ownership. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also reserve the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that this copy is being made available in this form by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner. ii Abstract RNA binding proteins (RBPs) control all aspects of RNA metabolism, and a single RBP can have numerous downstream effects. Alterations to their expression and/or function can, therefore, have remarkable consequences. For instance, decreased levels of the RNA binding motif domain (RBM) protein RBM5 are associated with increased risk of a number of cancer types, and RBM10 mutations can be lethal. Although these consequences are quite severe, little is known regarding the range of processes and events influenced by these two homologous RBPs. In fact, previous RBM5 and RBM10 functional studies were largely focused only on their abilities to promote two processes; apoptosis and cell cycle arrest. Potentially by control of these processes, RBM5 and RBM10 were shown to influence one event: differentiation. The objectives of this study were to identify all cellular processes and events enriched by changes in RBM5 and/or RBM10 expression in a particular cultured cell line, and to determine the extent of functional overlap for RBM5 and RBM10 in these cells. Towards these goals, a list of RBM5 and RBM10 mRNA targets and differentially expressed genes was determined using next generation sequencing techniques. Our data suggest that RBM5 and RBM10 do influence a wide range of cellular processes and events. Although there is overlap in RBM5 and RBM10 mRNA targets and differentially expressed genes, these RBPs can have antagonistic functions; for example our data suggest that RBM5 prevents the transformed state, whereas RBM10 actually promotes it in an RBM5-null environment. Furthermore, we present a working model by which RBM5 may regulate RBM10’s protransformatory function. Finally, we demonstrate a relationship between RBM5 and RBM10 in non-transformed cells. The results presented herein provide insight not only into the roles and regulation of RBM5 and RBM10, but of RBPs in general. Taken together, iii the results presented in the four papers included in this thesis expand the knowledge base of RBM5 and RBM10, which provides insight into the disease states associated with their disrupted expression or function. Our findings are thus relevant to a wide range of scientific fields including molecular, developmental and cancer biology. Keywords RNA binding proteins, RBM5, RBM10, RIP-Seq, RNA-Seq, Transcriptional studies, Small cell lung cancer, Myoblasts, Regulation of RNA binding proteins iv Co-Authorship Statement Chapter 2. Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site I determined RBM10 splice variant expression levels in GLC20 cells by RNA-Seq (Figure 2.3A). In addition, ST and I performed protein modeling. ST carried out all initial molecular biology experiments and is responsible for Figure 2.1D,E,F and Figure 2.2. CP performed the final RT- PCR experiment presented in Figure 2.1B. BK performed the final Western Blot presented in Figure 2.1Ci. JR performed the final NUMB RNA expression experiment, and produced the graph. AM performed the FISH analysis. LCS conceived the project and developed the model. ST prepared the first draft of the manuscript, and LCS wrote the final draft. Chapter 3. RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key transformation-associated pathways I wrote the manuscript, and my results are presented in all 8 tables and Figures 3.3, 3.4, 3.5 (Sp1 section only), 3.6, 3.7, 3.8, 3.11, 3.12, 3.13, and 3.14. JR grew the GLC20 cells (parental and sublines) (Figure 3.1F) and performed cell growth and apoptosis assays (Figures 3.9 and 3.10). LCS established the stable RBM5-expressing GLC20 sublines and revised the manuscript. JL, JR and LCS conceived and designed the experiments. Additional acknowledged contributions are as follow; NRM characterized the GLC20 cell line (Figures 3.1 and 3.2), BK analyzed RBM5 antibodies (Figure 3.5), ST help prepare RNA-Seq samples and SH extracted RNA from the primary tissue specimens. Chapter 4. RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5 I wrote the manuscript, prepared all figures and was corresponding author. My results are included in both tables and Figures 4.1, 4.2, 4.3A,B, 4.4, 4.5, 4.6A,B,D, 4.7, 4.8. I also developed the model (Figures 4.9 and 4.10). JR established the stable RBM10KD clones, and performed Western blot and MTT assays (Figure 4.3C,D,E and 4.6C). LCS revised the manuscript. Chapter 5. Post-transcriptional regulation of Rbm5 expression in undifferentiated H9c2 myoblasts I wrote the manuscript, prepared all figures and was corresponding author. Some work was performed by me at the end of my masters, but specifically during my PhD studies I performed transient RBM5 knockdown experiments (two biological replicates) (Figure 5.2) and analyzed RBM5 overexpression experiments (Figure 5.3). I also contributed to the analysis of the stable RBM5KD clones (Figure 5.1) and designed the model (Figure 5.4). LCS established the stable RBM5KD clones and revised the manuscript. ST screened all stable RBM5KD H9c2 clones generated by LCS (Figure 5.1). v Acknowledgments I would first and foremost like to thank my supervisor, Dr. Leslie Sutherland. You have been an amazing mentor, and words cannot express my gratitude. Your dedication to the success of your students is unmatched, and has shaped me into the researcher I have become. Thank you for your friendship, patience, support and encouragement, which have helped me through the more difficult times and taught me how to approach and overcome all new challenges. Thank you to my committee members, Dr. Éric Gauthier and Dr. Amadeo Parissenti, for their insights, guidance and support throughout my doctoral studies. Thank you also to the past and present members of the Sutherland lab group, particularly, Sarah Hunt, Jose Knee and Justin Roy, for supporting me through the ups and downs of research, and making the lab such a friendly and happy environment. To all members of the Health Sciences North Research Institute, it’s been a pleasure working alongside such exceptional researchers. I am very appreciative of the funding I received from the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Northern Cancer Foundation, which have allowed me to focus on research throughout my studies. A special thank you to my wonderful husband, Mathieu, who believes in me even when I don’t believe in myself. I will be forever grateful for your strong, unwavering love and support. Thank you also to Henri and Hugo, my two beautiful boys, who inspire me every day to be the best I can be. Finally, to my all of my family and friends, particularly my parents, I cannot thank you enough for your encouragement throughout all of my studies. Having such a strong support system has allowed me to dream big and accomplish this significant goal. vi Table of Contents Abstract .........................................................................................................................................
Recommended publications
  • Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma

    Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma

    Anatomy and Pathology Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma Sarah L. Lake,1 Sarah E. Coupland,1 Azzam F. G. Taktak,2 and Bertil E. Damato3 PURPOSE. To detect deletions and loss of heterozygosity of disease is fatal in 92% of patients within 2 years of diagnosis. chromosome 3 in a rare subset of fatal, disomy 3 uveal mela- Clinical and histopathologic risk factors for UM metastasis noma (UM), undetectable by fluorescence in situ hybridization include large basal tumor diameter (LBD), ciliary body involve- (FISH). ment, epithelioid cytomorphology, extracellular matrix peri- ϩ ETHODS odic acid-Schiff-positive (PAS ) loops, and high mitotic M . Multiplex ligation-dependent probe amplification 3,4 5 (MLPA) with the P027 UM assay was performed on formalin- count. Prescher et al. showed that a nonrandom genetic fixed, paraffin-embedded (FFPE) whole tumor sections from 19 change, monosomy 3, correlates strongly with metastatic death, and the correlation has since been confirmed by several disomy 3 metastasizing UMs. Whole-genome microarray analy- 3,6–10 ses using a single-nucleotide polymorphism microarray (aSNP) groups. Consequently, fluorescence in situ hybridization were performed on frozen tissue samples from four fatal dis- (FISH) detection of chromosome 3 using a centromeric probe omy 3 metastasizing UMs and three disomy 3 tumors with Ͼ5 became routine practice for UM prognostication; however, 5% years’ metastasis-free survival. to 20% of disomy 3 UM patients unexpectedly develop metas- tases.11 Attempts have therefore been made to identify the RESULTS. Two metastasizing UMs that had been classified as minimal region(s) of deletion on chromosome 3.12–15 Despite disomy 3 by FISH analysis of a small tumor sample were found these studies, little progress has been made in defining the key on MLPA analysis to show monosomy 3.
  • A Genome-Wide Association Study Lystra P

    A Genome-Wide Association Study Lystra P

    Hayden et al. Respiratory Research (2018) 19:209 https://doi.org/10.1186/s12931-018-0890-0 RESEARCH Open Access Childhood asthma is associated with COPD and known asthma variants in COPDGene: a genome-wide association study Lystra P. Hayden1,2* , Michael H. Cho2,3, Benjamin A. Raby1,2,3, Terri H. Beaty4, Edwin K. Silverman2,3, Craig P. Hersh2,3 and on behalf of the COPDGene Investigators Abstract Background: Childhood asthma is strongly influenced by genetics and is a risk factor for reduced lung function and chronic obstructive pulmonary disease (COPD) in adults. This study investigates self-reported childhood asthma in adult smokers from the COPDGene Study. We hypothesize that childhood asthma is associated with decreased lung function, increased risk for COPD, and that a genome-wide association study (GWAS) will show association with established asthma variants. Methods: We evaluated current and former smokers ages 45–80 of non-Hispanic white (NHW) or African American (AA) race. Childhood asthma was defined by self-report of asthma, diagnosed by a medical professional, with onset at < 16 years or during childhood. Subjects with a history of childhood asthma were compared to those who never had asthma based on lung function, development of COPD, and genetic variation. GWAS was performed in NHW and AA populations, and combined in meta-analysis. Two sets of established asthma SNPs from published literature were examined for association with childhood asthma. Results: Among 10,199 adult smokers, 730 (7%) reported childhood asthma and 7493 (73%) reported no history of asthma. Childhood asthmatics had reduced lung function and increased risk for COPD (OR 3.42, 95% CI 2.81–4.18).
  • Regulation of Pluripotency by RNA Binding Proteins

    Regulation of Pluripotency by RNA Binding Proteins

    Cell Stem Cell Review Regulation of Pluripotency by RNA Binding Proteins Julia Ye1,2 and Robert Blelloch1,2,* 1The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Center for Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94143, USA 2Department of Urology, University of California, San Francisco, San Francisco, CA 94143, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.stem.2014.08.010 Establishment, maintenance, and exit from pluripotency require precise coordination of a cell’s molecular machinery. Substantial headway has been made in deciphering many aspects of this elaborate system, particularly with respect to epigenetics, transcription, and noncoding RNAs. Less attention has been paid to posttranscriptional regulatory processes such as alternative splicing, RNA processing and modification, nuclear export, regulation of transcript stability, and translation. Here, we introduce the RNA binding proteins that enable the posttranscriptional regulation of gene expression, summarizing current and ongoing research on their roles at different regulatory points and discussing how they help script the fate of pluripotent stem cells. Introduction RBPs are responsible for every event in the life of an RNA Embryonic stem cells (ESCs), which are derived from the inner molecule, including its capping, splicing, cleavage, nontem- cell mass of the mammalian blastocyst, are remarkable because plated nucleotide addition, nucleotide editing, nuclear export, they can propagate in vitro indefinitely while retaining both the cellular localization, stability, and translation (Keene, 2007). molecular identity and the pluripotent properties of the peri-im- Overall, little is known about RBPs: most are classified based plantation epiblast.
  • RBM9 Antibody (Monoclonal) (M02) Mouse Monoclonal Antibody Raised Against a Partial Recombinant RBM9

    RBM9 Antibody (Monoclonal) (M02) Mouse Monoclonal Antibody Raised Against a Partial Recombinant RBM9

    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 RBM9 Antibody (monoclonal) (M02) Mouse monoclonal antibody raised against a partial recombinant RBM9. Catalog # AT3594a Specification RBM9 Antibody (monoclonal) (M02) - Product Information Application IF, WB, E Primary Accession O43251 Other Accession BC013115 Reactivity Human, Mouse Host mouse Clonality Monoclonal Isotype IgG2b Kappa Calculated MW 41374 RBM9 Antibody (monoclonal) (M02) - Additional Information Immunofluorescence of monoclonal antibody to RBM9 on A-431 cell. [antibody concentration 10 ug/ml] Gene ID 23543 Other Names RNA binding protein fox-1 homolog 2, Fox-1 homolog B, Hexaribonucleotide-binding protein 2, RNA-binding motif protein 9, RNA-binding protein 9, Repressor of tamoxifen transcriptional activity, RBFOX2, FOX2, HRNBP2, RBM9, RTA Target/Specificity RBM9 (AAH13115, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Dilution Antibody Reactive Against Recombinant WB~~1:500~1000 Protein.Western Blot detection against Immunogen (36.63 KDa) . Format Clear, colorless solution in phosphate buffered saline, pH 7.2 . Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Precautions RBM9 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures. Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 RBM9 Antibody (monoclonal) (M02) - Protocols Provided below are standard protocols that you may find useful for product applications. • Western Blot • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation • Flow Cytomety RBM9 monoclonal antibody (M02), clone • Cell Culture 5E11 Western Blot analysis of RBM9 expression in A-431 ( (Cat # AT3594a ) RBM9 monoclonal antibody (M02), clone 5E11.
  • Structural Basis for DEAH-Helicase Activation by G-Patch Proteins

    Structural Basis for DEAH-Helicase Activation by G-Patch Proteins

    Structural basis for DEAH-helicase activation by G-patch proteins Michael K. Studera, Lazar Ivanovica, Marco E. Webera, Sabrina Martia, and Stefanie Jonasa,1 aInstitute of Molecular Biology and Biophysics, Department of Biology, Swiss Federal Institute of Technology (ETH) Zürich, 8093 Zürich, Switzerland Edited by Joseph D. Puglisi, Stanford University School of Medicine, Stanford, CA, and approved February 21, 2020 (received for review August 12, 2019) RNA helicases of the DEAH/RHA family are involved in many essential RNA bases are stacked in the RNA binding channel between a long cellular processes, such as splicing or ribosome biogenesis, where β-hairpin in RecA2 (β14 to β15 in hsDHX15/scPrp43; SI Appendix, they remodel large RNA–protein complexes to facilitate transitions Fig. S1) and a conserved loop in RecA1 (termed “Hook-turn”). to the next intermediate. DEAH helicases couple adenosine tri- This means that during progression into the open state, the phosphate (ATP) hydrolysis to conformational changes of their β-hairpin and two other RNA-binding patches in RecA2 (termed catalytic core. This movement results in translocation along RNA, “Hook-loop” and “motif V”; SI Appendix, Fig. S1) have to shift 1 which is held in place by auxiliary C-terminal domains. The activity nucleotide (nt) toward the 5′ end of the RNA. Thus, when the of DEAH proteins is strongly enhanced by the large and diverse RecA domains close back up, at the start of the next hydrolysis class of G-patch activators. Despite their central roles in RNA me- cycle, the RNA is pushed by 1 nt through the RNA channel.
  • RBM5/LUCA-15 Tumour Suppression by Control of Apoptosis and the Cell

    RBM5/LUCA-15 Tumour Suppression by Control of Apoptosis and the Cell

    Review Article TheScientificWorldJOURNAL (2002) 2, 1885–1890 ISSN 1537-744X; DOI 10.1100/tsw.2002.859 RBM5/LUCA-15 —Tumour Suppression by Control of Apoptosis and the Cell Cycle? Mirna Mourtada-Maarabouni1 and Gwyn T. Williams2 School of Life Sciences, Keele University, Keele, Staffs, ST5 5BG, U.K. 1 2 TEL: 44 1782 583679, FAX 44 1782 583516; TEL: 44 1782 583032, FAX: 44 1782 583516 E-mail: [email protected]; [email protected] Received March 19, 2002; Revised May 17, 2002; Accepted May 17, 2002; Published July 4, 2002 The candidate tumour suppressor gene, LUCA-15, maps to the lung cancer tumour suppressor locus 3p21.3. The LUCA-15 gene locus encodes at least four alternatively spliced transcripts, which have been shown to function as regulators of apoptosis, a fact that may have a major significance in tumour regulation. This review highlights evidence that implicates the LUCA-15 locus in the control of apoptosis and cell proliferation, and reports observations that significantly strengthen the case for tumour suppressor activity by this gene. KEY WORDS: T-lymphocytes, LUCA-15, RNA-binding proteins, cell death, cell proliferation DOMAINS: cell death, cell cycle, oncology, gene regulation INTRODUCTION The molecular control of cancer is complex. Cancer genes are involved in the dysregulation of a whole range of normal cellular systemic processes including cell proliferation[1], cell-cell communication[2], DNA repair[3], chromosome stability[4], tumour invasion, motility and metastasis[5,6], apoptosis[7], and others. Despite impressive progress in recent years in understanding the molecular basis of cancer, many crucial genes remain to be identified.
  • Breakout Room 5 Poster Presentation Event

    Breakout Room 5 Poster Presentation Event

    Akshara Chandrabalan 2020 NSERC USRA Bioresource Engineering, Supervisor Dr. Prasher 2020 Undergraduate Student Research Awards Predicting Biochar Sorption Capacities Using VIEW THE POSTERS Artificial Neural Networks Poster Presentation Event Breakout Room 5 Daniel Moses 2020 NSERC USRA (ZOOM) SEPTEMBER 17, 2020 @ 4pm Parasitology, Supervisor Dr. Salavati In search of the cryptic motif VI on trypanosomatid RNA editing ligases Richard Boivin 2020 NSERC USRA Antoine Gaudreau 2020 NSERC USRA 1 Natural Resource Sciences, Supervisor Dr. Humphries Bioresource Engineering, Supervisor Dr. Akbarzadeh Muriel Wong Min 2020 AES Brown Martlet USRA Evaluating regional patterns of traditional wildlife 3D Printed Agricultural Wastes for Advanced Food Science & Ag. Chemistry, Supervisor Dr. Karboune harvest in northern Quebec Biocomposites A Database Platform for The Selection of Appropriate Fat Substitutes as "Natural" Katerina Lazaris 2020 NSERC USRA Rowena Groeneveld 2020 NSERC USRA Food Ingredients Animal Science, Supervisor Dr. Bordignon Parasitology, Supervisor Dr. Beech Review: Methods to Improve Oocyte Competence and Modelling of a ligand gated ion channel from embryo Development in Prepubertal Animals to Caenorhabditis elegans experimentally shown to bind Liana Fortin-Hamel 2020 NSERC USRA Accerlerate genetic Gain 6 dopamine Parasitology, Supervisor Dr. Scott 2 Trisha Sackey 2020 NSERC USRA Effects of maternal nematode infection on spatial Food Science & Ag.Chemistry, Supervisor Dr. George Alex Zvezdin 2020 NSERC USRA learning and memory of young mouse pups Natural Resource Sciences, Supervisor Dr. Head Genotypic and Phenotypic Profiling of Staphylo- coccus aureus strains isolated from Canadian Impacts of Agricultural Practices on Yellow Perch Xavier Godin 2020 NSERC USRA Dairy Cattle for Antimicrobial Resistance Spawning Sites in Lac-Saint Pierre Québec Plant Science, Supervisor Dr.
  • Supplemental Information Figure S1. Genome-Wide Alternative Splicing

    Supplemental Information Figure S1. Genome-Wide Alternative Splicing

    Supplemental information Figure S1. Genome-wide alternative splicing events affected by inducible expression SRSF3 in mouse MEF3T3 cells. To examine the effects of SRSF3 (SRp20) on genome-wide RNA splicing in mouse cells, we utilized Exonhit SpliceArray to compare genome-wide changes of RNA splicing and transcription in MEF3T3 mouse fibroblasts with or without ectopically inducible expression of SRp20. (A–C) Clustered heat maps for the top events regulated by SRSF3 identified by ExonHit splice arrays. SRSF3-targeted genes in three experimental repeats consist of 65 evidenced splicing events (A), 74 novel splicing events (B) and 11 genes with expression changes (C), with a threshold of ≥2-fold changes (p<0.01) in log2 as determined by a B/E method and FDR cutoff of 0.1 for gene expression change and 0.2 for splicing alternation. Individual gene names and event ID are indicated on the right. Event ID specifies individual splicing events being detailed in Supplementary Table S1-S3. MEF3T3 cells with an empty vector transfection were included as vector controls. Color key scales in log2 values are indicated at the bottom of each panel. The full list of B/E ratio analysis result is available at NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) (accession number GSE60147). Figure S2. Isoform profiling of mouse Ilf3 and human ILF3. (A) Diagrams of RNA isoforms of mouse Ilf3. Mouse Ilf3 consists of 22 exons and 21 introns, which produces 6 spliced isoforms of mRNAs by alternative splicing as illustrated. (B) Diagrams of splice isoforms of human ILF3. Human ILF3 gene consists of 21 exons (boxes) and 20 introns (lines between boxes), which produce 8 splice isoforms of mRNAs by alternative splicing as depicted.
  • Insight Into the Role of Alternative Splicing Within the Rbm10v1 Exon 10 Tandem Donor Site

    Insight Into the Role of Alternative Splicing Within the Rbm10v1 Exon 10 Tandem Donor Site

    Tessier et al. BMC Research Notes (2015) 8:46 DOI 10.1186/s13104-015-0983-5 SHORT REPORT Open Access Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site Sarah J Tessier1, Julie J Loiselle2, Anne McBain3, Celine Pullen1, Benjamin W Koenderink4, Justin G Roy5 and Leslie C Sutherland1,2,4,5,6,7* Abstract Background: RBM10 is an RNA binding protein involved in the regulation of transcription, alternative splicing and message stabilization. Mutations in RBM10, which maps to the X chromosome, are associated with TARP syndrome, lung and pancreatic cancers. Two predominant isoforms of RBM10 exist, RBM10v1 and RBM10v2. Both variants have alternate isoforms that differ by one valine residue, at amino acid 354 (RBM10v1) or 277 (RBM10v2). It was recently observed that a novel point mutation at amino acid 354 of RBM10v1, replacing valine with glutamic acid, correlated with preferential expression of an exon 11 inclusion variant of the proliferation regulatory protein NUMB, which is upregulated in lung cancer. Findings: We demonstrate, using the GLC20 male-derived small cell lung cancer cell line - confirmed to have only one X chromosome - that the two (+/−) valine isoforms of RBM10v1 and RBM10v2 result from alternative splicing. Protein modeling of the RNA Recognition Motif (RRM) within which the alteration occurs, shows that the presence of valine inhibits the formation of one of the two α-helices associated with RRM tertiary structure, whereas the absence of valine supports the α-helical configuration. We then show 2-fold elevated expression of the transcripts encoding the minus valine RBM10v1 isoform in GLC20 cells, compared to those encoding the plus valine isoform.
  • Investigating Developmental and Functional Deficits in Neurodegenerative

    Investigating Developmental and Functional Deficits in Neurodegenerative

    UNIVERSITY OF CALIFORNIA, IRVINE Investigating developmental and functional deficits in neurodegenerative disease using transcriptomic analyses DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Biomedical Sciences by Ryan Gar-Lok Lim Dissertation Committee: Professor Leslie M. Thompson, Chair Assistant Professor Dritan Agalliu Professor Peter Donovan Professor Suzanne Sandmeyer 2016 Introduction, Figure 1.1 © 2014 Macmillan Publishers Limited. Appendix 1 © 2016 Elsevier Ltd. All other materials © 2016 Ryan Gar-Lok Lim DEDICATION This dissertation is dedicated to my parents, sister, and my wife. I love you all very much and could not have accomplished any of this without your love and support. Please take the time to reflect back on all of the moments we’ve shared, and know, that it is because of those moments I have been able to succeed. This accomplishment is as much yours as it is mine. ii TABLE OF CONTENTS Page LIST OF FIGURES vi LIST OF TABLES ix ACKNOWLEDGMENTS x CURRICULUM VITAE xiii ABSTRACT OF THE DISSERTATION xv Introduction Huntington’s disease, the neurovascular unit and the blood-brain barrier 1 1.1 Huntington’s Disease 1.2 HTT structure and function 1.2.1 Normal HTT function and possible loss-of-function contributions to HD 1.3 mHTT pathogenesis 1.3.1 The dominant pathological features of mHTT - a gain-of- toxic function? 1.3.2 Cellular pathologies and non-neuronal contributions to HD 1.4 The neurovascular unit and the blood-brain barrier 1.4.1 Structure and function
  • Molecular Analyses of Malignant Pleural Mesothelioma

    Molecular Analyses of Malignant Pleural Mesothelioma

    Molecular Analyses of Malignant Pleural Mesothelioma Shir Kiong Lo National Heart and Lung Institute Imperial College Dovehouse Street London SW3 6LY A thesis submitted for MD (Res) Faculty of Medicine, Imperial College London 2016 1 Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer that is strongly associated with asbestos exposure. Majority of patients with MPM present with advanced disease and the treatment paradigm mainly involves palliative chemotherapy and best supportive care. The current chemotherapy options are limited and ineffective hence there is an urgent need to improve patient outcomes. This requires better understanding of the genetic alterations driving MPM to improve diagnostic, prognostic and therapeutic strategies. This research aims to gain further insights in the pathogenesis of MPM by exploring the tumour transcriptional and mutational profiles. We compared gene expression profiles of 25 MPM tumours and 5 non-malignant pleura. This revealed differentially expressed genes involved in cell migration, invasion, cell cycle and the immune system that contribute to the malignant phenotype of MPM. We then constructed MPM-associated co-expression networks using weighted gene correlation network analysis to identify clusters of highly correlated genes. These identified three distinct molecular subtypes of MPM associated with genes involved in WNT and TGF-ß signalling pathways. Our results also revealed genes involved in cell cycle control especially the mitotic phase correlated significantly with poor prognosis. Through exome analysis of seven paired tumour/blood and 29 tumour samples, we identified frequent mutations in BAP1 and NF2. Additionally, the mutational profile of MPM is enriched with genes encoding FAK, MAPK and WNT signalling pathways.
  • Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes

    Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes

    2137 Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes Joan P. Breyer,1 Kate M. McReynolds,1 Brian L. Yaspan,2 Kevin M. Bradley,1 William D. Dupont,3 and Jeffrey R. Smith1,2,4 Departments of 1Medicine, 2Cancer Biology, and 3Biostatistics, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine; and 4Medical Research Service, VA Tennessee Valley Healthcare System, Nashville, Tennessee Abstract The genetic variants underlying the strong heritable at genome-wide association study loci 8q24, 11q13, and À À component ofprostate cancer remain largely unknown. 2p15 (P =2.9Â 10 4 to P =4.7Â 10 5), showing study Genome-wide association studies ofprostate cancer population power. We also find evidence to support have yielded several variants that have significantly reported associations at candidate genes RNASEL, replicated across studies, predominantly in cases EZH2, and NKX3-1 (P = 0.031 to P = 0.0085). We unselected for family history of prostate cancer. further explore a set of candidate genes related to Additional candidate gene variants have also been RNASEL and to its role in retroviral restriction, proposed, many evaluated within familial prostate identifying nominal associations at XPR1 and RBM9. cancer study populations. Such variants hold great The effects at 8q24 seem more pronounced for those potential value for risk stratification, particularly for diagnosed at an early age, whereas at 2p15 and early-onset or aggressive prostate cancer, given the RNASEL the effects were more pronounced at a later comorbidities associated with current therapies. Here, age. However, these trends did not reach statistical we investigate a Caucasian study population of523 significance.